Overview

Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Zanamivir
Criteria
Inclusion Criteria:

- Subjects who meet the study population criteria

Exclusion Criteria:

- Subjects with a history of hypersensitivity to the ingredients of zanamivir